Hepatitis B infection and liver transplantation

Canadian Journal of Gastroenterology

Volumn 11, Issue 5, 1997, Pages 462-468

  Yoshida, Eric M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Transplant Society   (Canada)

Author keywords

Hepatitis B; Immunoglobulin; Larnivudine; Liver transplantation; Prophylaxis

Indexed keywords

ANTIVIRUS AGENT; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; LAMIVUDINE;

CLINICAL TRIAL; DRUG COST; HEPATITIS B; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REINFECTION; REVIEW; TREATMENT OUTCOME;

EID: 0030740699     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/1997/531514     Document Type: Review

References (3)

1. Nevens F, Goubau P, Van Eyken P, et al. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 1993;13:15-9.
2. Hoofnagle HH, Di Bisceglie AM, Waggoner JO, et al. Interferon alpha for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993;104:1116-21.
3. Perillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alpha in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995;109:908-16.